Adverse Drug Effects

Previous Short-Term Use Of Fenfluramine Not Associated With Increased Risk Of Drug-Related Heart Disease

Published in Drug Week, July 6th, 2001

No evidence of an increased risk of drug-related heart disease was found almost five years after discontinuation of a three-month course of weight loss therapy with fenfluramine, researchers report.

Fenfluramine is an anti-obesity agent with short-term indications to help with restricted energy intake. Fenfluramine hydrochloride was withdrawn from the U.S. market in September 1997 after reports of heart valve abnormalities in patients who used it. These patients predominately used phentermine hydrochloride in combination with fenfluramine (the much-reported phen-fen combination).

Ravin Davidoff, MB, BCh, from Boston University Medical Center,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2001-07-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry